196 related articles for article (PubMed ID: 30019138)
21. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.
Simoens SR
Med J Aust; 2011 Jan; 194(1):52-3; author reply 53-4. PubMed ID: 21449876
[No Abstract] [Full Text] [Related]
22. Comment on: "The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review".
Vílchez-Román C; Sanguinetti S; Mezones-Holguín E
Appl Health Econ Health Policy; 2019 Apr; 17(2):255-256. PubMed ID: 30370432
[No Abstract] [Full Text] [Related]
23. A comparative analysis of generics markets in five European countries.
Garattini L; Tediosi F
Health Policy; 2000 Apr; 51(3):149-62. PubMed ID: 10720685
[TBL] [Abstract][Full Text] [Related]
24. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
25. International comparison of generic medicine prices.
Simoens S
Curr Med Res Opin; 2007 Nov; 23(11):2647-54. PubMed ID: 17877848
[TBL] [Abstract][Full Text] [Related]
26. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.
Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z
BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250
[TBL] [Abstract][Full Text] [Related]
27. Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices.
Dane A; Klein Gebbink AS; Brugma JD; Degrassat-Théas A; Hug MJ; Houlind MB; Paubel P; van der Kuy PHM; Uyl-de Groot CA
Appl Health Econ Health Policy; 2023 Nov; 21(6):905-914. PubMed ID: 37751107
[TBL] [Abstract][Full Text] [Related]
28. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C.
Heath K
Clinicoecon Outcomes Res; 2018; 10():539-550. PubMed ID: 30288069
[TBL] [Abstract][Full Text] [Related]
30. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
31. Patent cliff mitigation strategies: giving new life to blockbusters.
Kakkar AK
Expert Opin Ther Pat; 2015; 25(12):1353-9. PubMed ID: 26372691
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic substitution post-patent expiry: the cases of ACE inhibitors and proton pump inhibitors.
Vandoros S
Health Econ; 2014 May; 23(5):621-30. PubMed ID: 23696193
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and Price Increases Among Sole-Source, Off-Patent Drugs in the United States, 2008 to 2018.
Alpern JD; Shahriar AA; Xi M; Thapa S; Kodet AJ; Stauffer WM; Vazquez Benitez G; Pawloski PA; Dehmer SP
JAMA Netw Open; 2020 Aug; 3(8):e2013595. PubMed ID: 32804216
[TBL] [Abstract][Full Text] [Related]
34. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
[TBL] [Abstract][Full Text] [Related]
35. A comparison of generic drug prices in seven European countries: a methodological analysis.
Wouters OJ; Kanavos PG
BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
[TBL] [Abstract][Full Text] [Related]
36. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
[TBL] [Abstract][Full Text] [Related]
37. Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction.
Rwagitinywa J; Sommet A; Palmaro A; Montastruc JL; Lapeyre-Mestre M
Health Policy; 2018 Mar; 122(3):237-242. PubMed ID: 29398158
[TBL] [Abstract][Full Text] [Related]
38. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
39. Generic medicine pricing in Europe: current issues and future perspective.
Simoens S
J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
[TBL] [Abstract][Full Text] [Related]
40. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
